DiaSorin SpA
MIL:DIA
DiaSorin SpA
PP&E Net
DiaSorin SpA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaSorin SpA
MIL:DIA
|
PP&E Net
€271.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
El En SpA
MIL:ELN
|
PP&E Net
€77.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
DiaSorin SpA
Glance View
In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation. From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.
See Also
What is DiaSorin SpA's PP&E Net?
PP&E Net
271.4m
EUR
Based on the financial report for Dec 31, 2024, DiaSorin SpA's PP&E Net amounts to 271.4m EUR.
What is DiaSorin SpA's PP&E Net growth rate?
PP&E Net CAGR 5Y
16%
Over the last year, the PP&E Net growth was 6%. The average annual PP&E Net growth rates for DiaSorin SpA have been -1% over the past three years , 16% over the past five years .
You don't have any saved screeners yet